

BCCA Protocol Summary for the Treatment of Hodgkin's Lymphoma using Cyclophosphamide, Vincristine and Prednisone

Protocol Code LYCCOP

Tumour Group Lymphoma

Contact Physician Dr. Laurie Sehn

ELIGIBILITY:

- Hodgkin's lymphoma
- Any age
- Only for patients who are undergoing cytoreductive chemotherapy prior to high dose chemotherapy and bone marrow transplantation

EXCLUSIONS:

- none

TESTS:

- Baseline: CBC, differential, platelets, HBsAg, HBcAb
- Before each treatment on Day 1 and Day 8: CBC, differential, platelets

PREMEDICATIONS:

Ondansetron 8 mg PO/IV pre-chemotherapy
 Dexamethasone 12 mg PO/IV pre-chemotherapy

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Cyclophosphamide	1200 mg/m ² on day 1 and 8	IV in 250-500 mL NS over 20-60 minutes
Vincristine	1.4 mg/m ² on day 1 and 8 (no maximum dose)	IV push (dilute vincristine to 20 mL with NS in a 30 mL syringe)
Prednisone	40 mg/m ² /day, day 1-14*	PO in am with food

*Round to the nearest 25 mg

Repeat every 28 days. Usually this protocol is given for 2 cycles before changing to the high dose treatment.

DOSE MODIFICATIONS:

1. **Hematological:**

ANC (x10 ⁹ /L)	Platelets (x10 ⁹ /L)	Dose (all drugs)
greater than 0.8	and greater than 80	100%
less than 0.8	or less than 80	If day 1, delay 1 week If day 8, omit cyclophosphamide

2. **Neurotoxicity:** vincristine only:

Toxicity	Dose Modification
Dysesthesias, areflexia only	100%
Abnormal buttoning, writing	67%
Motor neuropathy, moderate	50%
Motor neuropathy, severe	Omit

PRECAUTIONS:

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Extravasation:** Vincristine causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.
3. **Hepatitis B Reactivation:** All lymphoma patients should be tested for both HBsAg and HBcAb. If either test is positive, such patients should be treated with Lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

Call Dr. Laurie Sehn or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 01 Sep 2002 (replaced LYCOPP)

Date revised: 01 Feb 2011 (change contact physician)